JOP20190207A1 - تركيبة صيدلانية تشتمل على بونيسيمود - Google Patents
تركيبة صيدلانية تشتمل على بونيسيمودInfo
- Publication number
- JOP20190207A1 JOP20190207A1 JOP/2019/0207A JOP20190207A JOP20190207A1 JO P20190207 A1 JOP20190207 A1 JO P20190207A1 JO P20190207 A JOP20190207 A JO P20190207A JO P20190207 A1 JOP20190207 A1 JO P20190207A1
- Authority
- JO
- Jordan
- Prior art keywords
- ponesimod
- pharmaceutical combination
- active ingredient
- teriflunomide
- leflunomide
- Prior art date
Links
- LPAUOXUZGSBGDU-STDDISTJSA-N chembl1096146 Chemical compound O=C1N(C=2C(=CC=CC=2)C)C(=N/CCC)/S\C1=C/C1=CC=C(OC[C@H](O)CO)C(Cl)=C1 LPAUOXUZGSBGDU-STDDISTJSA-N 0.000 title abstract 2
- 229950009275 ponesimod Drugs 0.000 title abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 229960000681 leflunomide Drugs 0.000 abstract 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 abstract 1
- 229960000331 teriflunomide Drugs 0.000 abstract 1
- UTNUDOFZCWSZMS-YFHOEESVSA-N teriflunomide Chemical compound C\C(O)=C(/C#N)C(=O)NC1=CC=C(C(F)(F)F)C=C1 UTNUDOFZCWSZMS-YFHOEESVSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2017055994 | 2017-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20190207A1 true JOP20190207A1 (ar) | 2019-09-10 |
Family
ID=61655772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2019/0207A JOP20190207A1 (ar) | 2017-03-14 | 2017-06-16 | تركيبة صيدلانية تشتمل على بونيسيمود |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US11723896B2 (enExample) |
| EP (1) | EP3595657A1 (enExample) |
| JP (3) | JP7281406B2 (enExample) |
| KR (1) | KR102574562B1 (enExample) |
| CN (1) | CN110381942B (enExample) |
| AU (2) | AU2018233109B2 (enExample) |
| BR (1) | BR112019018894A2 (enExample) |
| CA (1) | CA3056301C (enExample) |
| CL (1) | CL2019002525A1 (enExample) |
| CO (1) | CO2019008510A2 (enExample) |
| CR (1) | CR20190464A (enExample) |
| DO (1) | DOP2019000257A (enExample) |
| EA (1) | EA201992117A1 (enExample) |
| EC (1) | ECSP19073317A (enExample) |
| IL (1) | IL269239B2 (enExample) |
| JO (1) | JOP20190207A1 (enExample) |
| MA (1) | MA49822A (enExample) |
| MX (1) | MX390941B (enExample) |
| NI (1) | NI201900092A (enExample) |
| PE (1) | PE20191489A1 (enExample) |
| PH (1) | PH12019502110A1 (enExample) |
| SG (1) | SG11201907308UA (enExample) |
| UA (1) | UA125756C2 (enExample) |
| WO (1) | WO2018167030A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190207A1 (ar) * | 2017-03-14 | 2019-09-10 | Actelion Pharmaceuticals Ltd | تركيبة صيدلانية تشتمل على بونيسيمود |
| US11014940B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Thiazolidinone and oxazolidinone compounds and formulations |
| US11186556B1 (en) | 2018-10-16 | 2021-11-30 | Celgene Corporation | Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof |
| US11013723B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms of a thiazolidinone compound, compositions and methods of use thereof |
| US11014897B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL178596C (nl) | 1975-06-05 | 1986-04-16 | Hoechst Ag | Werkwijze voor het bereiden van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor het bereiden van daarin als geneeskrachtige verbindingen te gebruiken 5-methylisoxazool-4-carbonzuuraniliden. |
| DE2854439A1 (de) | 1978-12-16 | 1980-07-03 | Hoechst Ag | Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung |
| US5268382A (en) | 1985-09-27 | 1993-12-07 | Hoechst Aktiengesellschaft | Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus |
| DE3534440A1 (de) | 1985-09-27 | 1987-04-02 | Hoechst Ag | Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes |
| US6723855B2 (en) * | 2000-02-15 | 2004-04-20 | Teva Pharmaceutical Industries Ltd. | Method for synthesizing leflunomide |
| AR033459A1 (es) | 2001-04-05 | 2003-12-17 | Aventis Pharma Inc | Uso de (41-trifluorometilfenil)-amida del acido (z)-2-ciano-3-hidroxi-but-2-enoico para el tratamiento de la esclerosis multiple |
| GB0123571D0 (en) | 2001-04-05 | 2001-11-21 | Aventis Pharm Prod Inc | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis |
| US6894184B2 (en) | 2003-03-18 | 2005-05-17 | Aventis Pharma Deutschland Gmbh | Process for preparing 2-cyano-3-hydroxy-N-(phenyl)but-2-enamides |
| USRE43833E1 (en) | 2003-11-21 | 2012-11-27 | Actelion Pharmaceuticals Ltd. | Thiazolidin-4-one derivatives |
| PL1689726T3 (pl) | 2003-11-21 | 2011-05-31 | Actelion Pharmaceuticals Ltd | Pochodne 5-(benz-(z)-ylideno)tiazolidyn-4-onu jako środki immunosupresyjne |
| CA2584655A1 (en) * | 2004-10-19 | 2006-04-27 | Aventis Pharmaceuticals Inc. | Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating inflammatory bowel disease |
| DE102006017896A1 (de) | 2006-04-13 | 2007-10-25 | Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg | Leflunomid enthaltende pharmazeutische Zusammensetzungen |
| US8912340B2 (en) | 2006-11-23 | 2014-12-16 | Actelion Pharmaceuticals Ltd. | Process for the preparation of 2-imino-thiazolidin-4-one derivatives |
| EP2489662B1 (en) | 2006-11-23 | 2014-08-06 | Actelion Pharmaceuticals Ltd. | Intermediates of a new process for the preparation of 5-benzylidene-2-alkylimino-3-phenylthiazolidin-4-one derivatives |
| BRPI0909625B1 (pt) | 2008-03-17 | 2021-09-08 | Actelion Pharmaceuticals Ltd | Agonista seletivo do receptor s1p1 para o uso como um medicamento, uso de um agonista seletivo do receptor s1p1 e kit contendo diferentes unidades de medicação de um agonista seletivo do receptor s1p1 |
| GB0819182D0 (en) | 2008-10-20 | 2008-11-26 | Actelion Pharmaceuticals Ltd | Crystalline forms |
| SI2477611T1 (sl) | 2009-09-18 | 2017-07-31 | Sanofi | Formulacije tablete (Z)-2-ciano-3-hidroksi-but-2-enojska kislina-(4'-trifluormetilfenil)-amida z izboljšano stabilnostjo |
| JP2013533286A (ja) | 2010-07-30 | 2013-08-22 | セントルイス ユニバーシティ | 疼痛を治療する方法 |
| EP2600861A1 (en) | 2010-08-02 | 2013-06-12 | Sanofi-Aventis U.S. LLC | Use of teriflunomide for treating multiple sclerosis |
| EP2692343A1 (en) | 2012-08-03 | 2014-02-05 | Forward Pharma A/S | Combination therapy for treatment of multiple sclerosis |
| HUE050733T2 (hu) | 2012-08-17 | 2021-01-28 | Actelion Pharmaceuticals Ltd | Eljárás (2Z,5Z)-5-(3-klór-4-((R)-2,3-dihidroxipropoxi)benzilidén)-2-(pro-pilimino)-3-(O-tolil)tiazolidin-4-on elõállítására és ezen eljárásban alkalmazott köztitermék |
| WO2016079687A1 (en) | 2014-11-18 | 2016-05-26 | Lupin Limited | Oral pharmaceutical composition of teriflunomide |
| MA41139A (fr) | 2014-12-11 | 2017-10-17 | Actelion Pharmaceuticals Ltd | Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1 |
| AU2015359346B2 (en) | 2014-12-11 | 2020-05-07 | Laboratoires Juvise Pharmaceuticals | Dosing regimen for a selective S1P1 receptor agonist |
| CN107920991A (zh) | 2015-06-18 | 2018-04-17 | 马丁尼斯生物制药纳米技术公司 | 治疗炎性疾病或病状的组合物和方法 |
| JOP20190207A1 (ar) * | 2017-03-14 | 2019-09-10 | Actelion Pharmaceuticals Ltd | تركيبة صيدلانية تشتمل على بونيسيمود |
-
2017
- 2017-06-16 JO JOP/2019/0207A patent/JOP20190207A1/ar unknown
-
2018
- 2018-03-13 WO PCT/EP2018/056185 patent/WO2018167030A1/en not_active Ceased
- 2018-03-13 PE PE2019001845A patent/PE20191489A1/es unknown
- 2018-03-13 JP JP2019549459A patent/JP7281406B2/ja active Active
- 2018-03-13 CA CA3056301A patent/CA3056301C/en active Active
- 2018-03-13 US US16/494,163 patent/US11723896B2/en active Active
- 2018-03-13 CN CN201880017102.0A patent/CN110381942B/zh active Active
- 2018-03-13 AU AU2018233109A patent/AU2018233109B2/en active Active
- 2018-03-13 EA EA201992117A patent/EA201992117A1/ru unknown
- 2018-03-13 CR CR20190464A patent/CR20190464A/es unknown
- 2018-03-13 BR BR112019018894A patent/BR112019018894A2/pt not_active Application Discontinuation
- 2018-03-13 SG SG11201907308UA patent/SG11201907308UA/en unknown
- 2018-03-13 MX MX2019010874A patent/MX390941B/es unknown
- 2018-03-13 EP EP18711299.0A patent/EP3595657A1/en active Pending
- 2018-03-13 MA MA049822A patent/MA49822A/fr unknown
- 2018-03-13 UA UAA201910123A patent/UA125756C2/uk unknown
- 2018-03-13 KR KR1020197026599A patent/KR102574562B1/ko active Active
-
2019
- 2019-08-05 CO CONC2019/0008510A patent/CO2019008510A2/es unknown
- 2019-09-03 CL CL2019002525A patent/CL2019002525A1/es unknown
- 2019-09-10 IL IL269239A patent/IL269239B2/en unknown
- 2019-09-11 NI NI201900092A patent/NI201900092A/es unknown
- 2019-09-13 PH PH12019502110A patent/PH12019502110A1/en unknown
- 2019-10-08 DO DO2019000257A patent/DOP2019000257A/es unknown
- 2019-10-10 EC ECSENADI201973317A patent/ECSP19073317A/es unknown
-
2022
- 2022-12-21 JP JP2022204487A patent/JP2023030091A/ja active Pending
-
2023
- 2023-06-27 US US18/341,853 patent/US20240139161A1/en active Pending
- 2023-11-29 AU AU2023274118A patent/AU2023274118B2/en active Active
-
2024
- 2024-04-18 JP JP2024067486A patent/JP2024096962A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019502110A1 (en) | Pharmaceutical combination comprising ponesimod | |
| MX2023011657A (es) | Composiciones que comprenden curones y usos de los mismos. | |
| GEP20207159B (en) | Diacylglycerol acyltransferase 2 inhibitors | |
| PL3668937T3 (pl) | Kompozycje i zastosowania Z-1-chloro-2,3,3,3-tetrafluoroprop-1-enu | |
| EP3677584A4 (en) | ASSOCIATION WITH BRUTON TYROSINKINASE (BTK) INHIBITION AND DEGRADATION | |
| NZ744307A (en) | Treatment of fibrosis | |
| MX2023005484A (es) | Analogos de carbamoil fenilalaninol y usos de los mismos. | |
| MY192425A (en) | Polymorphs | |
| JOP20180018A1 (ar) | تركيبات صيدلية تتضمن مثبط jak | |
| MX2020005483A (es) | Antagonistas de ildr2 y combinaciones de los mismos. | |
| PH12019501314A1 (en) | Pharmaceutical combination comprising a t-type calcium channel blocker | |
| SG11201907472QA (en) | Composition for inhibiting myofibrosis | |
| WO2020122838A3 (en) | A combination comprising a multiple sclerosis agent and at least one anti-epileptic agent | |
| MX376853B (es) | Odorante osmanthus. | |
| PH12018502008A1 (en) | Oral care product | |
| WO2018237010A3 (en) | VACCINE COMPOSITIONS AGAINST STREPTOCOCCUS AND THEIR METHODS OF USE | |
| CA3034993C (en) | COMPOSITE OF 3-PYRIDYLOXYPHENYLDIHYDROURACIL AND ITS USES | |
| MY179170A (en) | Insect repellent | |
| FI20155779A7 (fi) | Ei-steroidaalisen anti-inflammatorisen lääkkeen hidastetusti vapautuva annostelu | |
| MX2020003513A (es) | Composiciones de ingredientes activos que comprenden n-alquenoil-n-alquilglucamidas y el uso de los mismos. | |
| MX2020008300A (es) | Uso de [6]-paradol para estabilizacion de composiciones cosmeticas. | |
| MY202239A (en) | Combination of a mcl-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof | |
| EP3741373A4 (en) | USE OF CARRIMYCIN OR AN ACTIVE INGREDIENT OF IT | |
| EA201692056A1 (ru) | Композиция для личной гигиены | |
| CA3035001C (en) | COMPOUND OF PHENYL UREA AND ITS USES |